Zollinger-Ellison Syndrome Therapy Pipeline ReportLife Science Analytics (LSA)January 6, 2011 97 Pages - SKU: LSA6084670 |
|
The World Market for Pain Management Drugs and Devices
5/20/2013 | published by: Kalorama Information
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and
|
read more...
|
$3,500.00
|
|
Analysis of the Sexually-Transmitted Disease Testing Market in the US: Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis
6/14/2013 | published by: Venture Planning Group
This new 278-page report from Venture Planning Group provides analysis of the US sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. The report
|
read more...
|
$4,500.00
|
|
Triple Analysis: Breast Cancer, Leukemia and Melanoma
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology
|
read more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Lung Cancer and Melanoma
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment
|
read more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Angiogenesis
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a
|
read more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Prostate Cancer and Antibodies
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in
|
read more...
|
$5,175.00
|
|
Triple Analysis: Melanoma, Angiogenesis and Antibodies
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to
|
read more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Prostate Cancer
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment
|
read more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Leukemia and Melanoma
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology
|
read more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Lung Cancer and Melanoma
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment
|
read more...
|
$5,175.00
|
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Drug Discovery Reports
